Developing a Promising Smoking Cessation Drug with Favorable Safety Profile for a Large Market Opportunity| John Bencich, CEO, Achieve Life Sciences Inc. 00:10:00

Share On Facebook Share On Twitter

Achieve Life Sciences is pioneering the development of Cytisinicline, a promising smoking cessation drug with a superior safety profile compared to existing options, targeting a large market of potential beneficiaries amid rising e-cigarette usage.

Recent Videos